Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Edwards Lifesciences Corp.

Related EW
UPDATE: Morgan Stanley Raises PT On Edwards Lifesciences Corp., Say Upside Now Tied To Bull Case
Credit Suisse Raises 2015 TAVI Estimates for Edwards Lifesciences Corp.
Making Money With Charles Payne: 10/10/14 (Fox Business)

In a report published Friday, Jefferies & Company reiterated its Buy rating on Edwards Lifesciences Corp. (NYSE: EW), and raised its price target from $115.00 to $125.00.

Jefferies noted, “We published two physician surveys on transcatheter aortic valve replacement (TAVR), one of early adopters and the other of current non-users. Based on the results, which show strong and sustainable procedure growth, we are increasing our forecasts and target. We continue to rate EW shares Buy.”

Edwards Lifesciences Corp. closed on Thursday at $102.88.

Latest Ratings for EW

DateFirmActionFromTo
Dec 2014BarclaysMaintainsEqual-weight
Dec 2014Bank of AmericaMaintainsNeutral
Dec 2014Morgan StanleyMaintainsEqual-weight

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (EW)

Around the Web, We're Loving...

Get Benzinga's Newsletters